Loading…
Employees: 89
Size OmniAb (OABI) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $734M, the 2448th largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.24 on 6 Nov 2026.
Performance Over six months the shares gained 28.7%, against +9.6% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 10 in its peer set.
Growth Revenue grew 90.6% over the last twelve months (peer median -5.7%); the operating margin is -115.5% (peer median -1.3%).
Valuation It trades at 17.1× enterprise value to sales against a peer median of 1.9× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 60% a year for seven years (Req g). Recent delivered growth is -32%, so the hurdle is +91 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 25.8 points below its cost of capital (7.8% WACC).
Short interest Short interest is 5.9% of the free float (15 Oct 2026).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $40.2M | $18.7M | $26.4M | $34.2M | $59.1M |
| Revenue growth | — | -29% | -23% | -42% | — |
| Gross profit | $15.9M | -$3.39M | $6.71M | $14.7M | $42.8M |
| EBITDA | -$23.1M | -$49.8M | -$53.3M | -$49.7M | -$11.0M |
| Net income | -$43.5M | -$64.8M | -$62.0M | -$50.6M | -$22.3M |
| Free cash flow | $2.38M | -$37.0M | -$41.5M | $703,000 | -$20.8M |
| Capital expenditure | $286,000 | $565,000 | $1.88M | $1.64M | $17.2M |
| Total debt | $18.1M | $20.3M | $23.2M | $25.6M | $25.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OABI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.6% | +7.8% | 5th lowest of 10 |
| 6-month return | +28.7% | +9.6% | 5th highest of 10 |
| Distance from 52-week high | -19.7% | -27.7% | 5th highest of 10 |
| Revenue growth (TTM) | +90.6% | -5.7% | highest of 7 |
| Operating margin | -115.5% | -1.3% | 3rd lowest of 8 |
| EV / Sales | 17.1× | 1.9× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 59.6% | 16.5% | most demanding of 5 |
| Growth delivered (Del g) | -31.9% | +8.1% | lowest of 5 |
| Hurdle (Req g minus delivered) | +91.5 pp | -0.9 pp | most demanding of 5 |
| ROIC minus cost of capital | -25.8 pp | -8.6 pp | lowest of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OmniAb OABI | United States | $734M | +29% | +91% | -116% | 17.1× | 59.6% | -31.9% |
| Evotec EVT.DE | Germany | $630M | -33% | -8% | -19% | 0.8× | n/a | n/a |
| Adlai Nortye Ltd. Sponsored ADR ANL | United States | $619M | -23% | n/a | -134% | 22.8× | n/a | n/a |
| SBC Medical SBC | United States | $518M | +58% | -7% | 37% | 2.3× | -16.1% | -6.9% |
| Evolent Health EVH | United States | $518M | +10% | -4% | -1% | 0.6× | 22.6% | +15.2% |
| Oculis OCS | United States | $462M | -77% | n/a | n/a | n/a | n/a | n/a |
| Silence Therapeutics PLC Sponsored ADR SLN | United States | $1.23B | +184% | -97% | -10,478% | 1,889.5× | n/a | n/a |
| Tectonic Therapeutic TECX | United States | $403M | -29% | n/a | n/a | n/a | n/a | n/a |
| Fortrea FTRE | United States | $2.12B | +42% | -3% | 2% | 1.1× | 32.9% | +1.1% |
| Progyny PGNY | United States | $2.67B | +47% | +6% | 9% | 1.9× | 10.4% | +30.2% |